semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COPD Asthma Subjects must fulfil all of the following All patients with confirmed diagnosis of COPD (post-bronchodilator FEV1/FVC<0.7 based on the medical records) 1 or asthma (defined as those with a consistent history and prior documented evidence of variable airflow obstruction, with evidence of an increase in FEV1 greater than 12% or 400 mL following bronchodilator or bronchial hyperresponsiveness on bronchial provocation testing, when stable) 6 Aged >40 years old Signed written informed consent to participate in the study  Patients currently with acute exacerbation of COPD by GOLD definition (any worsening of a patient's respiratory symptoms that is beyond normal day-to-day variations and requires a change in medication) 1 or acute exacerbation of asthma by GINA guideline. 6 Patients with respiratory diseases that can show similar symptoms to chronic airway diseases such as bronchiectasis, tuberculosis (TB)-destroyed lung parenchyma, endobronchial TB, and lung cancer, or those who have history of these diseases based on physician's judgment Patients currently diagnosed with pneumonia and acute bronchitis Patients currently randomized in other clinical studies
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Cardiovascular Diseases Neuro-Degenerative Disease Cancer Pregnancy Men and women Older than 18 years Cardiovascular disease neurodegenerative disease Cancer Pregnancy  Inability to understand and to want Refusal to sign the informed consent
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Obstructive Pulmonary Disease Participants with a clinical diagnosis of COPD and who meet the following are eligible: 1. Recommended for Pulmonary Rehabilitation and minimum mMRC2 level of dyspnea 2. Motivated for participating in the project (and acceptance of randomization) 3. Sufficient mobility to attend PR  Certain comorbidities (e.g. unstable coronary complications) 2. Severe cognitive disabilities (e.g. dementia) 3. Inability to speak or understand Danish No previous singing experience or musical competence is required
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease COPD Copd Exacerbation Acute COPD Exacerbation Admission with acute exacerbation of COPD within 24 hours of presentation to hospital Age >40 Confirmed COPD diagnosis (FEV1/FVC <0.70 on spirometry) Willing to participate in the study and provide informed consent  Admission for reason other than COPD exacerbation e.g. Heart Failure Acute confusion as per clinical team Allergy or contraindication to combined bronchodilator medication Severe respiratory sepsis as evident by temperature >38 degrees and/or lobar pneumonia on Chest Radiograph Sustained tachycardia >120bpm Patients with very advanced COPD, admitted for palliative or long term care Patients re-admitted within 90 days who have already been enrolled in the study
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COPD known or first diagnosis of COPD lung function testing consistent with hyperinflation or peripheral obstruction emphysema in imaging symptoms (dyspnea, cough, sputum) and risk factors (>= 10 pack years) indication for bronchodilator therapy  GOLD stages 3 and 4 (spirometric) indication for dual bronchodilator therapy, triple therapy or inhaled steroid contraindication for cardiopulmonary exercise testing unwilling to participate
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Sleep one patient not relevant  - one patient not relevant
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 22.0-999.0,  Uncontrolled Hypertension English-speaking adults less than 60 years of age with BP measurements of ≥140/ ≥90 mm Hg years of age or older with BP measurements of ≥150/ ≥90 mm Hg diagnosed with diabetes with BP measurements of ≥140/ ≥90 mm Hg Patients with BP measurements of <180/ <110 mm Hg without hypertensive urgency symptoms  comorbidities of COPD, renal disease or chronic alcoholism -
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sepsis Septic Shock Critical Illness Fluid Overload Diagnosis of severe sepsis or septic shock within 12 hours of admission in our Intensive Care Unit (ICU) Informed consent  Age < 18 years Pregnancy Do Not Resuscitate (DNR/DNI) with limitations of care Patients with fatal underlying disease who are unlikely to survive to hospital discharge (e.g.: disseminated malignant disease) Patients primarily admitted for acute coronary syndromes, acute cerebrovascular incidents or active gastrointestinal (GI) bleeds Patients that need immediate surgical treatment Patients with HIV and a cell count of cluster of differentiation 4 (CD4) cells < 50 mm2 Patients with known glucose-6 phosphate dehydrogenase (G-6PD) deficiency Patients with severe sepsis/septic shock transferred from another hospital Patients with features of sepsis/septic shock > 24 hours
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cystic Fibrosis subject has confirmed diagnosis of cystic fibrosis (sweat chloride >60mmol/l and/or 2 mutations in the cftr gene known to cause cystic fibrosis) subject is able to perform informed consent  inability to give informed consent antibiotic therapy in the last 4 weeks prior to study start (exception: long term azithromycin therapy, long term antistaphylococcal therapy, long term inhaled antibiotics)
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Asthma Aged 18 years or older at the time of consent History of airflow obstruction as indicated by a pre-bronchodilator forced expiratory volume in one second (FEV1) <80 percent predicted recorded in the previous 12 months Documented evidence of a reversibility assessment within the previous 12 months, which demonstrated a post-bronchodilator increase in FEV1 of >=12 percent and >= 200 milliliters (mL) Diagnosed with moderate or severe asthma as defined by a stable maintenance inhaled corticosteroid (ICS) dose for at least 12 weeks prior to screening of; moderate: medium ICS dose > 250 and <=500 micrograms per day (mcg/day) fluticasone propionate (or equivalent) based on the total daily maintenance treatment dose; Severe: high ICS dose > 500 mcg/day fluticasone propionate (or equivalent) based on the total daily maintenance treatment dose Documented control status defined using the asthma control questionnaire (ACQ-6) items (ACQ-6) obtained at the time of screening Able to understand, read and speak English or Spanish sufficiently to complete all assessments Willing and able to take part in a telephone interview session Willing and able to provide written informed consent  Is a current smoker Has any medical condition that would preclude participation in this study, including the presence of emphysema or chronic bronchitis (COPD other than asthma) or a clinically important lung condition other than asthma such as current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis or diagnoses of an eosinophilic disorder such as eosinophilic esophagitis or a history of lung cancer Participated in an interventional study within the past 30 days
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Late-onset Pompe Disease Subject has a diagnosis of Pompe disease based on documented deficiency of GAA activity and a documented GAA mutation. 2. Male and female subjects between 18 years and 75 years, inclusive and ≥ 50 kg. 3. Subject must be currently receiving standard-of-care ERT (alglucosidase alfa) at a dose of 20 mg/kg dose every other week. 4. Subject must have been on ERT for the preceding 2 years or more. 5. Subject must have an upright forced vital capacity (FVC) within 35 to 90% of predicted normal (NHANES III reference values), based on the higher of the screening or baseline value, if their 6 minute walk distance (6MWD) is > 200 m. Subject must have an upright FVC within 40 to 90% of predicted normal (NHANES III reference values), based on the higher of the screening or baseline value, if their 6MWD is ≤ 200 m. If FVC is between 80 and 90% of predicted normal, the subject may enter the study if the percent predicted FVC value drops by 10% predicted or more in supine position 6. Subject is able to walk at least 100 m in the 6MWT and the assessment is noted as valid  Subject has received any investigational therapy or pharmacological treatment for Pompe disease, other than alglucosidase alfa within 30 days or 5 half lives, whichever is shorter, prior to the Baseline Visit or is anticipated to do so during the course of the study 2. Subject is on any of the following prohibited medications within 30 days of baseline miglitol (eg, Glyset) miglustat (eg, Zavesca) acarbose (eg, Precose, Glucobay) voglibose (eg, Volix, Vocarb, Volibo) 3. Subject requires use of invasive or non-invasive ventilatory support for > 6 hours a day while awake. 4. Subject has a medical or any other extenuating condition or circumstance that may, in the opinion of the investigator, pose an undue safety risk to the subject or compromise his/her ability to comply with protocol requirements. This includes clinical depression (as diagnosed by a psychiatrist or other mental health professional) with uncontrolled or poorly controlled symptoms. 5. Subject is breastfeeding, or is pregnant or planning to become pregnant within the next 2 years. 6. Other according to the Lumizyme/Myozyme instructions for use
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD Dyspnea Age ≥ 40 Ability to provide consent COPD diagnosis Forced Expiratory Volume in one second (FEV1) <55 and ≥ 25 percent of predicted value Perceived Shortness of Breath via the Modified Medical Research Counsel Dyspnea questionnaire (rating of 2 or greater) (Appendix B) Able to follow directions Able to tolerate mild physical activity Pursed Lip Breathing as standard of care No evidence of bullous lung disease (with any bullae greater than 3cm in diameter) as confirmed by a CT scan within the past one year  Subjects who are acutely ill, medically complicated or who are medically unstable as determined by the investigator Suffering from COPD exacerbation at time of enrollment or 60 days prior Subjects who are not currently prescribed oxygen and manifest oxygen desaturation below 88% on the screening 6MWT Subjects with heart disease or neuromuscular disease Subjects who are not prescribed short-acting bronchodilator medication Patients who have experienced recent barotrauma or pneumothorax Unstable angina or Myocardial Infarction during past month Uncontrolled Hypertension (systolic blood pressure of >180mmHg (millimeters of Mercury) and a diastolic >100mmHg) Heart Rate >120 at rest Subjects who have trouble coordinating their breathing with the device during the device training, or cannot tolerate the device mouthpiece resulting in leaks from the nasal cavity
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Asthma Chronic Obstructive Pulmonary Disease Part 1 male subjects aged 18-55 years inclusive healthy subjects based on medical evaluation including medical history,physical examination, laboratory tests and cardiac testing Body Mass Index (BMI) between 18.5 and 32.0 kg/m2 extremes inclusive Non or ex-smokers who smoked < 5 pack years (pack-years = the number of cigarette packs per day times the number of years) and stopped smoking > 1 year Good physical and mental status, determined on the basis of the medical history and a general clinical examination Lung function equal to or more than 80% of predicted normal value and FEV1/FVC ratio > 0.70; Part 2 Adult male and female subjects aged 18 to 75 years Clinical diagnosis of mild persistent asthma  Part1 Any clinically relevant abnormabilites and/or uncontrolled diseases Abnormal laboratory values Recent respiratory tract infection Hypersensitivity to the drug excipients Positive serology results Positive cotinine, alcohol, drug of abuse tests Part 2 Pregnant and/or breast-feeding women Subjects with a medical history or current diagnosis of COPD or any other pulmonary disease other than asthma Subjects who have cardiovascular condition
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  COPD Tobacco Use At least 10 pack year smoking history Daily use of at least 5 cigarettes No plan to quit cigarettes in the next 30 days Willing to use e-cigarettes Diagnosis of COPD (FEV1/forced vital capacity [FVC] <0.70) with mild (FEV1 >80% predicted) or moderate (FEV1 <80% but >50% predicted) airflow limitation (post-bronchodilator); confirmed by spirometry English-speaking  Past 30-day use of nicotine-containing products (cigars, cigarillos, hookah, electronic cigarettes, smokeless tobacco, nicotine replacement therapy) Past 30 day use of inhaled drugs (marijuana, crack) Pregnant or breastfeeding Planning to become pregnant within the next 3 months or unable to agree to use appropriate contraception during study Pulmonary disease other than COPD or asthma Ever requiring mechanical ventilation or more hospitalizations for COPD in the past 12 months Cardiac hospitalization in the past 6 months Active chest pain or palpitations Uncontrolled hypertension (blood pressure >160/100)